In a preliminary study, 38 preserved human homologous saphenous vein grafts were used for secondary vascular access in 36 chronic hemodialysis patients. Cumulative oneyear patency was 67%. Twelve grafts failed, 10 owing to thrombosis and 2 owing to infection. Overall complication rate, morbidity, and patency were compatible with the other available graft materials. A prospective randomized trial of Varivas graft against PTFE has been instigated.
Get full access to this article
View all access options for this article.
References
1.
1. Palder SB, Kirkman RL, Whittemore AD, et al: Vascular access for hemodialysis. Ann Surg202:235-239, 1985.
2.
2. Tellis VA, Kohlberg WI, Bhat DJ, et al: Expanded polytetrafluoroethylene graft fistula for chronic hemodialysis. Ann Surg189:101-105, 1979.
3.
3. Jenkins AMcL, Buist TAS, Glover SD: Medium term follow up of forty autogenous vein and forty polytetrafluoroethylene (Gore Tex) grafts for vascular access. Surgery88:667-667, 1980.
4.
4. Munda R, First MR, Alexander JW, et al: Polytetrafluoroethylene graft survival in hemodialysis. JAMA249:219-219, 1983.
5.
5. Brems J, Castaneda M, Garvin PJ: A five-year experience with the bovine heterograft for vascular access. Arch Surg121:941-944, 1986.
6.
6. Raju S: PTFE grafts for hemodialysis access. Ann Surg206:666-673, 1987.
